文献速递脊柱关节炎

依那西普治疗疑似非放射学中轴型脊柱关节炎无效:6个月安慰剂对照试验

Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2021-03-24

该研究纳入无TNF抑制剂使用史、炎性背痛且至少2项SpA特征、高疾病活动度(BASDAI≥4)但不要求骶髂关节MRI阳性或CRP升高的疑似非放射学中轴型SpA患者,随机接受依那西普(n=40)或安慰剂(n=40)治疗16周,主要终点ASAS20应答在两组间无显著差异(16.7% vs 11.1%,RR 0.7,95%CI 0.2-2.2,P=0.5),结论为依那西普治疗无效。

要点

  • 疑似非放射学中轴型SpA且不要求MRI阳性或CRP升高者,依那西普16周ASAS20应答与安慰剂无差异。
  • 停药后8周内依那西普组BASMI、CRP和ESR恶化程度大于安慰剂组,CRP差异显著。
  • 该研究提示对此类患者人群不应常规使用TNF抑制剂治疗。

核心结论

  • 在疑似非放射学中轴型SpA且高疾病活动度但不要求骶髂关节MRI阳性或CRP升高的患者中,依那西普治疗16周无效。

研究设计与样本

  • 随机(1:1)、安慰剂对照试验,纳入无TNF抑制剂使用史、炎性背痛且至少2项SpA特征、BASDAI≥4的患者,依那西普组n=40,安慰剂组n=40,治疗16周后停药随访至24周。

主要发现

  • 16周时ASAS20应答率依那西普组6例(16.7%),安慰剂组4例(11.1%),相对风险0.7(95%CI 0.2-2.2),P=0.5。
  • 16周时仅ESR在依那西普组较安慰剂组改善更明显(分别下降2.2 mm/小时和1.4 mm/小时),但差异无统计学意义。
  • 16至24周停药期间,依那西普组BASMI、CRP和ESR恶化程度大于安慰剂组,其中CRP差异显著。

关键数值与推荐

  • 主要终点为16周ASAS20应答率。
  • 次要终点包括ASDAS及16周和24周时BASMI、CRP、ESR和加拿大脊柱关节炎研究联盟指数(骶髂关节MRI)评分的变化。

临床怎么用

  • 对于疑似非放射学中轴型SpA且无MRI阳性或CRP升高的高疾病活动度患者,不应常规使用依那西普治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy of 16-week treatment with etanercept (ETN) in patients with suspected nonradiographic axial spondyloarthritis (SpA). METHODS: Tumor necrosis factor inhibitor-naive patients with inflammatory back pain with at least 2 SpA features and high disease activity (Bath Ankylosing Spondylitis Disease Activity Index score ≥4), without the requirement of a positive finding on magnetic resonance imaging (MRI) of the sacroiliac (SI) joint and/or elevated C-reactive protein (CRP) level, were randomized (1:1) to receive ETN (n = 40) or placebo (n = 40) for 16 weeks and subsequently were followed up for a further 8 weeks (to 24 weeks from baseline) without study medication. The primary end point was the Assessment of SpondyloArthritis international Society 20 (ASAS20) response at 16 weeks. Secondary end points included the Ankylosing Spondylitis Disease Activity Score (ASDAS) and changes in disease parameters, including the Bath Ankylosing Spondylitis Metrology Index (BASMI), CRP level, erythrocyte sedimentation rate (ESR), and Spondyloarthritis Research Consortium of Canada index scores (MRI of the SI joint), after 16 and 24 weeks. RESULTS: Patient characteristics at baseline were comparable between the ETN and placebo groups. At 16 weeks, there was no significant difference in the percentage of patients exhibiting ASAS20 response between the ETN group (6 patients [16.7%]) and the placebo group (4 patients [11.1%]) (relative risk 0.7 [95% confidence interval 0.2-2.2], P = 0.5). Only the ESR showed more improvement in the ETN group compared to the placebo group at 16 weeks (decreases of 2.2 mm/hour and 1.4 mm/hour, respectively), but the difference did not reach statistical significance. Between 16 and 24 weeks, without study medication, the BASMI, CRP level, and ESR had worsened to a greater extent in the ETN group compared to the placebo group, with the difference being significant for the CRP level. CONCLUSION: This study shows that in patients with suspected nonradiographic axial SpA with high disease activity but without the requirement of a positive finding on SI joint MRI and/or elevated CRP level, treatment with ETN is not effective.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Rusman T, van der Weijden MAC, Nurmohamed MT, et al. Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial. Arthritis Rheumatol. 2021. PMID: 33277982. doi:10.1002/art.41607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。